Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.
Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06527404 |
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis |
TERMINATED | PHASE3 |
| NCT06376045 |
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma |
TERMINATED | PHASE2 |
| NCT05899816 |
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) |
COMPLETED | PHASE3 |
| NCT05882877 |
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) |
TERMINATED | PHASE3 |
| NCT05724199 |
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) |
COMPLETED | PHASE3 |
| NCT05651711 |
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) |
COMPLETED | PHASE3 |
| NCT05633355 |
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) |
COMPLETED | PHASE3 |
| NCT05398445 |
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) |
COMPLETED | PHASE3 |
